

WORKING DRAFT

|  |
| --- |
|  |

**GUIDANCE DOCUMENT**

Structured Product Labeling (SPL) -

Validation Rules for the Product Monograph

|  |
| --- |
|  |

Published by authority of the

Minister of Health

|  |
| --- |
|  |

|  |  |
| --- | --- |
| **Adopted Date** | ??? |
| **Effective Date** | ??? |

**Health Products and Food Branch**



|  |  |
| --- | --- |
| Our mission is to help the people of Canada maintain and improve their health.  *Health Canada* | The Health Products and Food Branch (HPFB)’s mandate is to take an integrated approach to managing the health-related risks and benefits of health products and food by:   * Minimizing health risk factors to Canadians while maximizing the safety provided by the regulatory system for health products and food; and, * Promoting conditions that enable Canadians to make healthy choices and providing information so that they can make informed decisions about their health.   *Health Products and Food Branch* |

© Minister of Public Works and Government Services Canada 209

***Également disponible en français sous le titre :*** *Ligne directrice: Monographie de produit*

**FOREWORD**

Guidance documents are meant to provide assistance to industry and health care professionals on **how** to comply with the policies and governing statutes and regulations. They also serve to provide review and compliance guidance to staff, thereby ensuring that mandates are implemented in a fair, consistent and effective manner.

Guidance documents are administrative instruments not having force of law and, as such, allow for flexibility in approach. Alternate approaches to the principles and practices described in this document ***may be*** acceptable provided they are supported by adequate scientific justification. Alternate approaches should be discussed in advance with the relevant program area to avoid the possible finding that applicable statutory or regulatory requirements have not been met.

As a corollary to the above, it is equally important to note that Health Canada reserves the right to request information or material, or define conditions not specifically described in this guidance, in order to allow the Department to adequately assess the safety, efficacy or quality of a therapeutic product. Health Canada is committed to ensuring that such requests are justifiable and that decisions are clearly documented.

This document should be read in conjunction with the accompanying notice and the relevant sections of other applicable guidance’s.

**DOCUMENT REVISION HISTORY**

|  |  |  |  |
| --- | --- | --- | --- |
| **File name** | ??? | **Replaces** | N/A |
| **Date Adopted**  **Effective Date** | ???  ??? | **Date Adopted**  **Effective Date** | N/A  N/A |

|  |  |  |  |
| --- | --- | --- | --- |
| **Version** | **Location of Change** | **Change Made** | **Effective Date** |
| 1 | Not Applicable | Initial Issuance of Guidance | ??? |
|  |  |  |  |

**TABLE OF CONTENTS**

[1 Introduction & General Information 1](#_Toc492041684)

[1.1 Purpose 1](#_Toc492041685)

[1.2 Content 1](#_Toc492041686)

[1.3 Order 1](#_Toc492041687)

[1.4 Scope 1](#_Toc492041688)

[2 General 1](#_Toc492041689)

[3 Document Prolog 2](#_Toc492041690)

[3.1 Document Prolog Validation: 2](#_Toc492041691)

[4 Document Information 2](#_Toc492041692)

[4.1 Document Information Validation: 2](#_Toc492041693)

[5 Author Information 3](#_Toc492041694)

[5.1 Author Information Validation 3](#_Toc492041695)

[6 Product Data Elements Section 4](#_Toc492041696)

[6.1 Brand Name Validation 4](#_Toc492041697)

[6.2 Proper (Proper/Common) Name Validation 4](#_Toc492041698)

[6.3 DosageForm Validation 4](#_Toc492041699)

[6.4 StrengthValue Validation 4](#_Toc492041700)

[6.5 StrengthUnit Validation 5](#_Toc492041701)

[6.6 StrengthPerDosageValue Validation 5](#_Toc492041702)

[6.7 DosageUnit Validation 5](#_Toc492041703)

[6.8 RouteofAdministration Validation 5](#_Toc492041704)

[6.9 ActiveIngredients Validation 5](#_Toc492041705)

[6.10 Clinically Relevant Nonmedicinal Ingredients Validation 5](#_Toc492041706)

[7 Labeling Section Information 6](#_Toc492041707)

[7.1 General Validation 6](#_Toc492041708)

[7.2 Part I: Health Professional Information Section Validation 17](#_Toc492041709)

[7.3 Part II: Scientific Information Section Validation 17](#_Toc492041710)

[7.4 Part III: Consumer Information Section Validation 17](#_Toc492041711)

[7.5 Scheduling Symbol Section Validation 17](#_Toc492041712)

[7.6 Pharmaceutical Standard Section Validation 17](#_Toc492041713)

[7.7 Therapeutic Classification Section Validation 18](#_Toc492041714)

[7.8 Sponsor Name Section Validation 18](#_Toc492041715)

[7.9 Sponsor Address Section Validation 18](#_Toc492041716)

[7.10 Other Party Name Section Validation 18](#_Toc492041717)

[7.11 Other Party Address Section Validation 18](#_Toc492041718)

[7.12 Date of Preparation Section Validation 19](#_Toc492041719)

[7.13 Date of Revision Section Validation 19](#_Toc492041720)

[7.14 Submission Control No Section Validation 19](#_Toc492041721)

[7.15 Summary Product Information Section Validation 19](#_Toc492041722)

[7.16 Indications and Clinical Use Section Validation 19](#_Toc492041723)

[7.17 Contradictions Section Validation 19](#_Toc492041724)

[7.18 Warnings and Precautions Section Validation 20](#_Toc492041725)

[7.19 Adverse Reactions Section Validation 20](#_Toc492041726)

[7.20 Drug Interactions Section Validation 20](#_Toc492041727)

[7.21 Dosage and Administration Section Validation 20](#_Toc492041728)

[7.22 Overdosage Section Validation 20](#_Toc492041729)

[7.23 Action and Clinical Pharmacology Section Validation 20](#_Toc492041730)

[7.24 Storage and Stability Section Validation 21](#_Toc492041731)

[7.25 Special Handling Instructions Section Validation 21](#_Toc492041732)

[7.26 Dosage Forms, Composition and Packaging Section Validation 21](#_Toc492041733)

[7.27 Pharmaceutical Information Section Validation 21](#_Toc492041734)

[7.28 Clinical Trials Section Validation 21](#_Toc492041735)

[7.29 Detailed Pharmacology Section Validation 21](#_Toc492041736)

[7.30 Microbiology Section Validation 21](#_Toc492041737)

[7.31 Toxicology Section Validation 21](#_Toc492041738)

[7.32 References Section Validation 21](#_Toc492041739)

[7.33 About This Medication Section Validation 21](#_Toc492041740)

[7.34 Serious Warnings and Precautions Section Validation 22](#_Toc492041741)

[7.35 Interactions with this Medication Section Validation 22](#_Toc492041742)

[7.36 Proper Use of this Medication Section Validation 22](#_Toc492041743)

[7.37 Side Effects and What to Do About Them Section Validation 22](#_Toc492041744)

[7.38 How to Store It Section Validation 22](#_Toc492041745)

[7.39 Reporting Suspected Side Effects Section Validation 22](#_Toc492041746)

[7.40 More Information Section Validation 22](#_Toc492041747)

[7.41 Footnote Section Validation 22](#_Toc492041748)

[7.42 Title Page Validation 22](#_Toc492041749)

[7.43 Title Block Validation 23](#_Toc492041750)

[7.44 Part 3: Revision DateSection Validation 23](#_Toc492041751)

[7.45 General Section Validation 23](#_Toc492041752)

[7.46 Opening Disclaimer Section Validation 23](#_Toc492041753)

[7.47 Table Of Contents Section Validation 23](#_Toc492041754)

[7.48 Title Page Warning Box Validation 23](#_Toc492041755)

[7.49 Title Page General Information Validation 23](#_Toc492041756)

[7.1 Description Section Validation 23](#_Toc492041757)

[7.2 Radiation Dosimetry Section Validation 23](#_Toc492041758)

[7.3 Recent Major Label Changes 24](#_Toc492041759)

[7.4 Serious Warnings and Precautions BoxValidation 24](#_Toc492041760)

[7.5 Non-clinical Toxicology Section Validation 24](#_Toc492041761)

[7.6 Supporting Product Monographs Validation 24](#_Toc492041762)

[7.7 Interactions Section Validation 24](#_Toc492041763)

[7.8 Proper Use Section Validation 24](#_Toc492041764)

[7.9 Side Effects Section Validation 24](#_Toc492041765)

[7.10 Storage Section Validation 24](#_Toc492041766)

# Introduction & General Information

This section will outline the intent of guidance document along with general information on the guidance document.

## Purpose

The purpose of this technical guidance document is to assist with the overall technical validation of the Product Monograph (PM) using as a Structured Product Labeling (SPL) document.

The guidance document is limited to the technical aspects of validating a PM, it is a companion to the business related PM Guidance document, it extends the HPFB Structured Product Labelling (SPL) – General Validation Rules for all Document Types document.

This technical guidance document only contains specifics relating to the structured Product Monograph, that means all general rules are omitted and detailed in the general SPL validation documents.

## Order

The Business Guidance details the presentation and sequence of the information as well as the layout and formatting.

This guidance document presents the information based on the section ID and the order the element occurs in the associated schema. Several aspects of the information such as the Document and Author sections are not exposed to the user and the Product Data Element sections is embedded in the content of the document rather than exposed as a separate section.

## Scope

As outlined in the purpose information above, any aspect of the guidance that is common to all HPFB SPL documents is omitted from this document, this includes any structure, element, or attribute that is common.

As an example in the Document Information section only 3 elements are described even though the Document Information section has 9 elements.

# General

Outlined in this section are all PM specific aspects that apply to the overall document, aspects that are common to all HPFB SPL documents are omitted from this document.

1. For simplicity only the English display name has been included in this document, the display names are detailed in the controlled vocabulary (CV) documentation.
2. Numbers (1) are used to detail technical conformance requirements; validation rules are detailed directly below the requirements and are organized using letters (a).
3. Only items that have specific Doctype validation are included.

# Document Prolog

Outlined in this section are all PM specific aspects relating to the Document prolog.

## Document Prolog Validation:

1. There is a ?xml-stylesheet declaration for both xsl and the css
   1. DT Rule 49 validates the overall Processing Instructions.
2. The location of the stylesheet is: <https://raw.githubusercontent.com/HealthCanada/Structured-Content-Information/master/Structured-Product-Labeling-(SPL)/Style-Sheets/SPM/current/spl.xsl>
   1. DT Rule 50 validates the file path of the Processing Instructions.
3. The type is text/xsl
   1. DT Rule 50 validates the file path of the Processing Instructions.
4. The location of the stylesheet is: <https://raw.githubusercontent.com/HealthCanada/Structured-Content-Information/master/Structured-Product-Labeling-(SPL)/Style-Sheets/SPM/current/spl.css>
   1. DT Rule 50 validates the file path of the Processing Instructions.
5. The type is text/css
   1. DT Rule 50 validates the file path of the Processing Instructions.

# Document Information

Outlined in this section are all PM specific aspects relating to the Document Information.

## Document Information Validation:

1. The < templateId@extension > value shall be as detailed in the following table:

| **Document Template** | **templateId@extension Value** |
| --- | --- |
| 2004 Standard Product Monograph | 1 |
| 2004 NOCC Product Monograph | 2 |
| 2004 Subsequent Entry Product Product Monograph | 3 |
| 2004 Schedule C Product Monograph | 4 |
| 2004 Schedule D Product Monograph | 5 |
| 2016 Standard Product Monograph | 6 |
| 2016 NOCC Product Monograph | 7 |
| 2016 Subsequent Entry Product Product Monograph | 8 |
| 2016 Schedule C Product Monograph | 9 |
| 2016 Schedule D Product Monograph | 10 |

1. There is a <title>.
   1. DT Rule 2 checks for the absence of the title element.

# Author Information

1. Undefined company ID’s are not allowed
   1. DT Rule 6 identifies that the companyId is 999999999

# Product Data Elements Section

Outlined below are the specifics relating to the PM Product Data, this excludes all overall document and labeling content information.

## Proper (Proper/Common) Name Validation

1. For each Brand Name there shall be a corresponding Proper Name.
   1. DT Rule 33 checks that the number of Brand Names and Proper Names are the same.
2. There may not be any Proper Name that does not have a corresponding Brand Name.
   1. Validated by DT Rule 33

## DosageForm Validation

1. For each Brand Name there shall be a corresponding DosageForm.
   1. DT Rule 34 checks that the number of Brand Names and DosageForms are the same.
2. There may not be any DosageForm that does not have a corresponding Brand Name.
   1. Validated by DT Rule 34.

## StrengthValue Validation

1. For each Brand Name there shall be a corresponding StrengthValue.
2. There may not be any StrengthValue that does not have a corresponding Brand Name.

## StrengthUnit Validation

1. For each Brand Name there shall be a corresponding StrengthUnit.
2. There may not be any StrengthUnit that does not have a corresponding Brand Name.

## StrengthPerDosageValue Validation

1. For each Brand Name there shall be a corresponding StrengthPerDosage.
2. There may not be any StrengthPerDosage that does not have a corresponding Brand Name.

## DosageUnit Validation

1. For each Brand Name there shall be a corresponding DosageUnit.
2. There may not be any DosageUnit that does not have a corresponding Brand Name.

## RouteofAdministration Validation

1. For each Brand Name there shall be a corresponding RouteofAdministration.
   1. DT Rule 35 checks that the number of Brand Names and RouteofAdministration elements are the same.
2. There may not be any RouteofAdministration that does not have a corresponding Brand Name.
   1. Validated by DT Rule 35.

## ActiveIngredients Validation

1. For each Brand Name element there shall be one or more corresponding ActiveIngredients element(s)
2. There may not be any ActiveIngredients that does not have a corresponding Brand Name.

## Clinically Relevant Nonmedicinal Ingredients Validation

1. Zero or more NonmedicinalIngredients elements are permitted.
2. There may not be any NonmedicinalIngredients elements that do not have a corresponding Brand Name.

# Labeling Section Information

Outlined below are the specifics relating to the PM Content Sections. Sections may contain sub sections as well as content unless specified in the section validation rules.

## General Validation

1. The Section Details are encoded in OID 2.16.840.1.113883.2.20.6.36 (structure-aspects), it is included in Annex A as a reference, it details the <code@code> value, as well as the heading level and cardinality for each labeling section:
   1. DT Rule 36, identifies that an inappropriate section was included
   2. DT Rule 37, identifies that an incorrect number of sections were included.
   3. DT Rule 40, identifies that the section sequence does not match the IG.

## Part I: Health Professional Information Section Validation

1. This section shall not contain any content other than nested content sections.
   1. DT Rule 43 and 44 identify that there is content.

## Part II: Scientific Information Section Validation

1. This section shall not contain any content other than nested content sections.
2. DT Rule 43 and 44 identify that there is content.

## Part III: Consumer Information Section Validation

1. This section shall not contain any content other than nested content sections.
2. DT Rule 43 and 44 identify that there is content.

## Scheduling Symbol Section Validation

1. The Scheduling Symbol section may contain 1:n subsections.
2. No content is permitted in this section.
   1. DT Rule 43, 44, 45 identify that there is content.
3. Each Scheduling Symbol subsections shall have a <code@codeSystem> with the value: “2.16.840.1.18883.3.989.5.1.4.1.1”
4. Each Scheduling Symbol subsections shall have a <code@code> value representing a single Scheduling Symbol, derived from OID: 2.16.840.1.18883.3.989.5.1.4.1.1.
5. No content is permitted in any Scheduling Symbol subsections.
6. Scheduling Symbol subsections do not have a <title>.

## Pharmaceutical Standard Section Validation

1. The Pharmaceutical Standard section may contain 1:n subsections.
2. No content is permitted in the Pharmaceutical Standard Section.
3. Each Pharmaceutical Standard section shall have a <code@codeSystem> with the value: “2.16.840.1.18883.3.989.5.1.4.1.5”
4. Each Pharmaceutical Standard subsections shall have a <code@code> value representing a single Scheduling Symbol derived from OID: 2.16.840.1.18883.3.989.5.1.4.1.5.
5. No content is permitted in any Pharmaceutical Standard subsection.
6. Pharmaceutical Standard subsections do not have a <title>.

## Therapeutic Classification Section Validation

1. The Therapeutic Classification section may contain 0:n subsections.
2. No content is permitted in the Therapeutic Classification Section.
3. Each Therapeutic Classification section shall have a <code@codeSystem> with the value: “2.16.840.1.18883.3.989.5.1.4.1.6”
4. Each Therapeutic Classification subsections shall have a <code@code> value representing a single Therapeutic Classification derived from OID: 2.16.840.1.18883.3.989.5.1.4.1.6.
5. No content is permitted in any Therapeutic Classification subsection.
6. Therapeutic Classification subsections do not have a <title>.

## Sponsor Name Section Validation

1. The Sponsor Name Section is mandatory and corresponds to the <representedOrganization> element in the Author Section.
2. There is a single Sponsor Name Section.

## Sponsor Address Section Validation

1. The Sponsor Address Section is mandatory and corresponds to the <representedOrganization> element in the Author Section.
2. There is a single Sponsor Address Section.

## Other Party Section Validation

1. There may be one or more parties identified in the Other Party Section
   1. This section corresponds to the name aspects of the <assignedEntity> element in the Author Section of this document.
2. For each party there shall be a Role.
3. For each party there shall be a Name.

## Date of Preparation Section Validation

1. The content of the Date of Preparation Section is limited to a single date.
2. The Date of Preparation must be earlier than or equal to the date the document is received.
3. The Date of Preparation is not modified after the initial submission, the Date of Revision is used.

## Date of Revision Section Validation

1. The Date of Revision Section is mandatory when the revision number for the document is greater than 1.0, and it shall remain empty for version 1.0.
2. The content of the Date of Revision Section is limited to a single date.
3. The Date of Revision must be must be earlier than or equal to the date the document is received.

## Submission Control No Section Validation

1. Each Submission Control No Section may have a single Submission Control value.
2. The content of a Submission Control value is the Submission ID.

## Title Page Validation

1. The Title Page Section is an exception and shall not have a Title.
2. This section shall not contain any content other than nested content sections.
   1. DT Rule 43 and 44 identify that there is content.

## Title Block Validation

1. The Title Block Section is an exception and shall not have a Title.

## Part 3: Revision DateSection Validation

1. The content of this section is a single date.

## Table Of Contents Section Validation

1. The Table Of Contents Section is Auto generated and contains no editable content.
2. The Table Of Contents Section shall include all H1, H2, H3, H4 & H5 level sections outlined in the General Validation Section.
3. The generated Table Of Contents shall include a hyperlink to each entry.

## Title Page Warning Box Validation

1. The Title Block Section is an exception and shall not have a Title.

## Serious Warnings and Precautions BoxValidation

1. This section is an exception and shall not have a Title.

Annex A – OID 2.16.840.1.113883.2.20.6.36 (structure-aspects)

| **Code** | **Level** | **Card.** | **Title** | **<Code@displayName> (Language=ENG)** | **TemplateId Exception** |
| --- | --- | --- | --- | --- | --- |
| 450 | N/A | 1:1 | N/A | Title Page | None |
| 460 | N/A | 1:1 | N/A | Title Block | None |
| 50 | H2 | 1:1 | F | Document Information | None |
| 60 | H2 | 1:1 | F | Scheduling Symbol | None |
| 70 | N/A | 1:n | F | Brand Name | None |
| 80 | N/A | 1:n | F | Proper Name | None |
| 90 | N/A | 1:n | F | Dosage Form(s) | None |
| 100 | N/A | 1:n | F | Strength(s) | None |
| 60 | H2 | 1:1 | F | Pharmaceutical Standard | None |
| 70 | H2 | 1:1 | F | Therapeutic Classification | None |
| 530 | N/A | 1:1 | N/A | Title Page Box Warning | Only applicable to: 2, 7 |
| 80 | H2 | 1:1 | F | Sponsor Name | None |
| 90 | H2 | 1:1 | F | Sponsor Address | None |
| 500 | H2 | 0:n | F | Other Party Name | None |
| 510 | H2 | 0:n | F | Other Party Address | None |
| 100 | H2 | 1:1 | F | Date Of Preparation | None |
| 160 | H2 | 1:1 | F | Date Of Revision | None |
| 170 | H2 | 1:n | F | Submission Control Number | None |
| 440 | H2 | 0:1 | F | Footnote | None |
| 540 | H2 | 1:1 | F | Title Page General Information | Only applicable to: 2, 7 |
| 520 | H2 | 1:1 | F | Table Of Contents | None |
| 20 | H1 | 1:1 | F | Part I: Health Professional Information | None |
| 180 | H2 | 1:1 | F | Summary Product Information | None |
| 550 | H2 | 1:1 | F | Description | Only applicable to: 4, 5 |
| 550-10 | H3 | 1:1 | F | Physical Characteristics | Only applicable to: 4 |
| 550-20 | H3 | 1:1 | F | External Radiation | Only applicable to: 4 |
| 190 | H2 | 1:n | F | Indications And Clinical Use | None |
| 190-10 | H3 | 1:1 | F | Patient Subsets | None |
| 190-10-10 | H4 | 1:1 | F | Geriatrics | None |
| 190-10-20 | H4 | 1:1 | F | Pediatrics | None |
| 580 | H2 | 0:1 | F | Serious Warnings and Precautions Box | Only applicable to: 6, 7, 8, 9, 10 |
| 200 | H2 | 1:1 | F | Contraindications | None |
| 550 | H2 | 1:1 | F | Description | Only applicable to: 10 |
| 210 | H2 | 1:1 | F | Warnings And Precautions | None |
| 580 | H3 | 0:1 | F | Serious Warnings and Precautions Box | Only applicable to: 1, 2, 3, 4, 5 |
| 210-10 | H3 | 0:1 | F | General | Only applicable to: 9 |
| 210-240 | H3 | 1:1 | F | Contamination | None |
| 210-250 | H3 | 1:1 | F | Local Skin Reactions at Vaccination Sites | Only applicable to: 10 |
| 210-20 | H3 | 0:1 | F | Carcinogenesis And Mutagenesis | None |
| 210-30 | H3 | 0:1 | F | Cardiovascular | None |
| 210-240 | H3 | 1:1 | F | Contamination | Only applicable to: 4 |
| 210-40 | H3 | 0:1 | F | Dependence/Tolerance | None |
| 210-260 | H3 | 0:1 | F | Driving and Operating Machinery | Only applicable to: 8, 9, 10 |
| 210-50 | H3 | 0:1 | F | Ear/Nose/Throat | None |
| 210-60 | H3 | 0:1 | F | Endocrine And Metabolism | None |
| 210-70 | H3 | 0:1 | F | Gastrointestinal | None |
| 210-80 | H3 | 0:1 | F | Genitourinary | None |
| 210-90 | H3 | 0:1 | F | Hematologic | None |
| 210-100 | H3 | 0:1 | F | Hepatic/Biliary/Pancreatic | None |
| 210-60 | H3 | 0:1 | F | Immune | None |
| 210-250 | H3 | 1:1 | F | Local Skin Reactions at Vaccination Sites | Only applicable to: 4 |
| 210-230 | H3 | 1:1 | F | Monitoring And Laboratory Tests | Only applicable to: 8, 9, 10 |
| 210-70 | H3 | 0:1 | F | Neurologic | None |
| 210-80 | H3 | 0:1 | F | Ophthalmologic | None |
| 210-90 | H3 | 0:1 | F | Peri-Operative Considerations | None |
| 210-100 | H3 | 0:1 | F | Psychiatric | None |
| 210-160 | H3 | 0:1 | F | Renal | None |
| 210-170 | H3 | 0:1 | F | Respiratory | None |
| 210-180 | H3 | 0:1 | F | Sensitivity/Resistance | None |
| 210-190 | H3 | 0:1 | F | Sexual Function/Reproduction | Not applicable to: 6, 7, 8, 9, 10 |
| 210-200 | H3 | 0:1 | F | Skin | Not applicable to: 6, 7, 8, 9, 10 |
| 210-270 | H3 | 0:1 | F | Sexual Health | Only applicable to: 6, 7, 8, 9, 10 |
| 210-270-10 | H4 | 0:1 | F | Reproduction | Only applicable to: 6, 7, 8, 9, 10 |
| 210-270-20 | H4 | 0:1 | F | Function | Only applicable to: 6, 7, 8, 9, 10 |
| 210-270-30 | H4 | 0:1 | F | Fertility | Only applicable to: 6, 7, 8, 9, 10 |
| 210-200 | H3 | 0:1 | F | Skin | Only applicable to: 6, 7, 8, 9, 10 |
| 210-210 | H3 | 0:1 | F | Special Populations | None |
| 210-210-10 | H4 | 0:1 | F | Pregnant Women | None |
| 210-210-20 | H4 | 0:1 | F | Nursing Women | None |
| 210-210-30 | H4 | 0:1 | F | Pediatrics | None |
| 210-210-40 | H4 | 0:1 | F | Geriatrics | None |
| 210-210-60 | H4 | 0:n | M | Special Populations - Misc. | Only applicable to: 1, 2, 3, 4, 5 |
| 210-230 | H4 | 1:1 | F | Monitoring And Laboratory Tests | Only applicable to: 1, 2, 3, 4, 5 |
| 220 | H2 | 1:1 | F | Adverse Reactions | None |
| 650 | H3 | 0:1 | F | Serious Adverse Reactions Box | None |
| 220-80 | H3 | 0:1 | F | General | Only applicable to: 6, 7, 8, 9, 10 |
| 220-10 | H3 | 0:1 | F | Adverse Drug Reaction (ADR) Overview | None |
| 220-20 | H3 | 0:1 | F | Clinical Trial Adverse Drug Reactions | None |
| 220-30 | H3 | 0:1 | F | Less Common Clinical Trial Adverse Drug Reactions | None |
| 220-90 | H3 | 0:1 | F | Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and other Quantitative Data | Only applicable to: 6, 7, 8, 9, 10 |
| 220-40 | H3 | 0:1 | F | Abnormal Hematologic And Clinical Chemistry Findings | None |
| 220-100 | H3 | 0:1 | F | Clinical Trial Adverse Reactions (Pediatrics) | Only applicable to: 6, 7, 8, 9, 10 |
| 220-50 | H3 | 0:1 | F | Post-Market Adverse Drug Reactions | None |
| 230 | H2 | 1:1 | F | Drug Interactions | None |
| 660 | H3 | 0:1 | F | Serious Drug Interactions Box | None |
| 230-80 | H3 | 1:1 | F | Overview | None |
| 230-10 | H3 | 0:1 | F | Drug-Drug Interactions | None |
| 230-20 | H3 | 0:1 | F | Drug-Food Interactions | None |
| 230-30 | H3 | 0:1 | F | Drug-Herb Interactions | None |
| 230-40 | H3 | 0:1 | F | Drug-Laboratory Test Interactions | None |
| 230-50 | H3 | 0:1 | F | Drug-Lifestyle Interactions | None |
| 240 | H2 | 1:1 | F | Dosage And Administration | None |
| 240-10 | H3 | 1:1 | F | Dosing Considerations | None |
| 240-60 | H3 | 1:1 | F | Dosage | Only applicable to: 4 |
| 240-70 | H3 | 1:1 | F | Image Acquisition and Interpretation | Only applicable to: 4 |
| 240-80 | H3 | 1:1 | F | Instructions for Preparation and Use | Only applicable to: 4 |
| 240-90 | H3 | 1:1 | F | Directions for Quality Control | Only applicable to: 4 |
| 240-20 | H3 | 1:1 | F | Recommended Dose And Dosage Adjustment | None |
| 240-30 | H3 | 1:1 | F | Missed Dose | None |
| 240-40 | H3 | 0:1 | F | Administration | None |
| 240-50 | H3 | 0:1 | F | Reconstitution | None |
| 240-50-10 | H4 | 0:1 | F | Oral Solutions | None |
| 240-50-20 | H4 | 0:1 | F | Parenteral Products | None |
| 240-60 | H3 | 1:1 | F | Dosage | Only applicable to: 9 |
| 240-70 | H3 | 1:1 | F | Image Acquisition and Interpretation | Only applicable to: 9 |
| 240-80 | H3 | 1:1 | F | Instructions for Preparation and Use | Only applicable to: 9 |
| 240-90 | H3 | 1:1 | F | Directions for Quality Control | Only applicable to: 9 |
| 560 | H2 | 1:1 | F | Radiation Dosimetry | Only applicable to: 9 |
| 550 | H2 | 1:1 | F | Description | Only applicable to: 9 |
| 550-10 | H3 | 1:1 | F | Physical Characteristics | Only applicable to: 9 |
| 550-20 | H3 | 1:1 | F | External Radiation | Only applicable to: 9 |
| 250 | H2 | 1:1 | F | Overdosage | None |
| 260 | H2 | 1:1 | F | Action And Clinical Pharmacology | None |
| 260-10 | H3 | 1:1 | F | Mechanism Of Action | None |
| 260-20 | H3 | 1:1 | F | Pharmacodynamics | None |
| 260-30 | H3 | 1:1 | F | Pharmacokinetics | None |
| 260-30-10 | H4 | 0:n | F | Absorption | None |
| 260-30-20 | H4 | 0:n | F | Distribution | None |
| 260-30-30 | H4 | 0:n | F | Metabolism | None |
| 260-30-40 | H4 | 0:n | F | Excretion | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50 | H4 | 0:n | F | Special Populations And Conditions | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50-10 | H5 | 0:n | F | Pediatrics | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50-20 | H5 | 0:n | F | Geriatrics | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50-30 | H5 | 0:n | F | Gender | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50-40 | H5 | 0:n | F | Race | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50-50 | H5 | 0:n | F | Hepatic Insufficiency | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50-60 | H5 | 0:n | F | Renal Insufficiency | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-50-70 | H5 | 0:n | F | Genetic Polymorphism | Not applicable to: 6, 7, 8, 9, 10 |
| 260-30-70 | H4 | 0:n | F | Elimination | Only applicable to: 6, 7, 8, 9, 10 |
| 260-40 | H3 | 1:1 | F | Duration of Effect | Only applicable to: 5 |
| 560 | H2 | 1:1 | F | Radiation Dosimetry | Only applicable to: 4 |
| 270 | H2 | 1:1 | F | Storage And Stability | None |
| 280 | H2 | 0:1 | F | Special Handling Instructions | None |
| 290 | H2 | 1:1 | F | Dosage Forms, Composition And Packaging | None |
| 30 | H1 | 1:1 | F | Part II: Scientific Information | None |
| 300 | H2 | 1:1 | F | Pharmaceutical Information | None |
| 300-10 | H3 | 1:n | F | Drug Substance | None |
| 300-10-10 | H4 | 1:n | F | Proper Name | None |
| 300-10-20 | H4 | 1:1 | F | Chemical Name | None |
| 300-10-30 | H4 | 1:1 | F | Molecular Formula And Molecular Mass | None |
| 300-10-40 | H4 | 1:1 | F | Structural formula, including relative and absolute stereochemistry | None |
| 300-10-50 | H4 | 1:1 | F | Physicochemical Properties | None |
| 300-20 | H2 | 1:1 | F | Product Characteristics | Only applicable to: 4, 5, 9, 10 |
| 300-30 | H3 | 1:1 | F | Viral Inactivation | Only applicable to: 5, 10 |
| 310 | H2 | 1:1 | F | Clinical Trials | None |
| 310-10 | H3 | 0:1 | F | Efficacy and Safety Studies | None |
| 310-10-10 | H4 | 0:1 | F | Study Demographics And Trial Design | None |
| 310-10-20 | H4 | 0:1 | F | Study Results | None |
| 310-20 | H3 | 0:1 | F | Pivotal Comparative Bioavailability Studies | None |
| 320 | H2 | 1:1 | F | Detailed Pharmacology | Only applicable to: 1, 2, 3, 4, 5 |
| 330 | H2 | 0:1 | F | Microbiology | Only applicable to: 1, 2, 3, 4, 5 |
| 340 | H2 | 0:1 | F | Toxicology | Only applicable to: 1, 2, 3, 4, 5 |
| 350 | H2 | 0:1 | F | References | Only applicable to: 1, 2, 3, 4, 5 |
| 330 | H2 | 0:1 | F | Microbiology | Only applicable to: 6, 7, 8, 9, 10 |
| 590 | H2 | 0:1 | F | Non-clinical Toxicology | Only applicable to: 6, 7, 8, 9, 10 |
| 600 | H2 | 0:1 | F | Supporting Product Monographs | Only applicable to: 6, 7, 8, 9, 10 |
| 40 | H1 | 1:n | F | Part III: Consumer Information | None |
| 480 | N/A | 1:1 | F | General | None |
| 490 | H2 | 1:1 | F | Opening Disclaimer | None |
| 360 | H2 | 1:1 | F | About This Medication | None |
| 360-10 | H3 | 1:1 | F | What The Medication Is Used For | Only applicable to: 1, 2, 3, 4, 5 |
| 360-20 | H3 | 1:1 | F | What It Does | Only applicable to: 1, 2, 3, 4, 5 |
| 360-30 | H3 | 1:1 | F | When It Should Not Be Used | Only applicable to: 1, 2, 3, 4, 5 |
| 360-40 | H3 | 1:1 | F | What The Medicinal Ingredient Is | Only applicable to: 1, 2, 3, 4, 5 |
| 360-50 | H3 | 1:1 | F | What The Important Nonmedicinal Ingredients Are | Only applicable to: 1, 2, 3, 4, 5 |
| 360-60 | H3 | 1:1 | F | What Dosage Forms It Comes In | Only applicable to: 1, 2, 3, 4, 5 |
| 360-70 | H3 | 1:1 | F | What is <Brand name> used for? | Only applicable to: 6, 7, 8, 9, 10 |
| 360-80 | H3 | 1:1 | F | How does <Brand name> work? | Only applicable to: 6, 7, 8, 9, 10 |
| 360-90 | H3 | 1:1 | F | What are the ingredients in <Brand name>? | Only applicable to: 6, 7, 8, 9, 10 |
| 360-100 | H3 | 1:1 | F | <Brand name> comes in the following dosage forms: | Only applicable to: 6, 7, 8, 9, 10 |
| 360-60 | H3 | 1:1 | F | Do not use <Brand name> if: | Only applicable to: 6, 7, 8, 9, 10 |
| 370 | H2 | 1:1 | F | Warnings And Precautions | None |
| 370-10 | H3 | 0:1 | F | To help avoid side effects and ensure proper use, talk to your healthcare professional before you take <Brand name> | Only applicable to: 6, 7, 8, 9, 10 |
| 370-20 | H3 | 0:1 | F | Other warnings you should know about: | Only applicable to: 6, 7, 8, 9, 10 |
| 380 | H2 | 1:1 | F | Interactions With This Medication | Only applicable to: 1, 2, 3, 4, 5 |
| 610 | H2 | 1:1 | F | Interactions | Only applicable to: 6, 7, 8, 9, 10 |
| 610-10 | H3 | 0:1 | F | Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines. | Only applicable to: 6, 7, 8, 9, 10 |
| 610-20 | H3 | 0:1 | F | The following may interact with <Brand name>: | Only applicable to: 6, 7, 8, 9, 10 |
| 390 | H2 | 1:1 | F | Proper Use Of This Medication | Only applicable to: 1, 2, 3, 4, 5 |
| 390-10 | H3 | 1:1 | F | Usual Dose | Only applicable to: 1, 2, 3, 4, 5 |
| 390-20 | H3 | 1:1 | F | Overdose | Only applicable to: 1, 2, 3, 4, 5 |
| 390-30 | H3 | 1:1 | F | Missed Dose | Only applicable to: 1, 2, 3, 4, 5 |
| 620 | H2 | 1:1 | F | Proper Use | Only applicable to: 6, 7, 8, 9, 10 |
| 620-10 | H3 | 1:1 | F | How to take <Brand name>: | Only applicable to: 6, 7, 8, 9, 10 |
| 620-20 | H3 | 1:1 | F | Usual dose | Only applicable to: 6, 7, 8, 9, 10 |
| 620-30 | H3 | 1:1 | F | Overdose | Only applicable to: 6, 7, 8, 9, 10 |
| 620-40 | H3 | 1:1 | F | Missed dose | Only applicable to: 6, 7, 8, 9, 10 |
| 400 | H2 | 1:1 | F | Side Effects And What To Do About Them | Only applicable to: 1, 2, 3, 4, 5 |
| 410 | H2 | 1:1 | F | How To Store It | Only applicable to: 1, 2, 3, 4, 5 |
| 420 | H2 | 1:1 | F | Reporting Suspected Side Effects | Only applicable to: 1, 2, 3, 4, 5 |
| 630 | H2 | 1:1 | F | Side Effects | Only applicable to: 6, 7, 8, 9, 10 |
| 630-10 | H3 | 1:1 | F | What are possible side effects from using <Brand name>? | Only applicable to: 6, 7, 8, 9, 10 |
| 640 | H2 | 1:1 | F | Storage | Only applicable to: 6, 7, 8, 9, 10 |
| 430 | H2 | 1:1 | F | More Information | None |
| 430-10 | H3 | 1:1 | F | If you want more information about <Brand name>: | Only applicable to: 6, 7, 8, 9, 10 |
| 470 | N/A | 1:1 | N/A | Part 3 Revision Date | None |
| 48780-1 | N/A | 1:1 | F | SPL Product Data Elements Section | None |